NY-ESO-1 TCR

Drug Profile

NY-ESO-1 TCR

Alternative Names: anti-NY-ESO-1 TCR

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action CTAG1B protein inhibitors; Gene transference; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Meningioma; Solid tumours

Most Recent Events

  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 16 Sep 2017 Jonsson Comprehensive Cancer Center plans a phase I trial for Cancer (Late-stage disease) in USA (NCT03240861)
  • 07 Nov 2015 Phase II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top